RU2013122770A - Антитела для лечения вич - Google Patents
Антитела для лечения вич Download PDFInfo
- Publication number
- RU2013122770A RU2013122770A RU2013122770/10A RU2013122770A RU2013122770A RU 2013122770 A RU2013122770 A RU 2013122770A RU 2013122770/10 A RU2013122770/10 A RU 2013122770/10A RU 2013122770 A RU2013122770 A RU 2013122770A RU 2013122770 A RU2013122770 A RU 2013122770A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- cdr
- antibody
- amino acid
- hiv
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 13
- 239000012634 fragment Substances 0.000 claims abstract 9
- 150000001875 compounds Chemical class 0.000 claims abstract 8
- 239000000427 antigen Substances 0.000 claims abstract 5
- 102000036639 antigens Human genes 0.000 claims abstract 5
- 108091007433 antigens Proteins 0.000 claims abstract 5
- 230000036436 anti-hiv Effects 0.000 claims abstract 4
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- 230000010076 replication Effects 0.000 claims abstract 2
- 208000031886 HIV Infections Diseases 0.000 claims 5
- 208000037357 HIV infectious disease Diseases 0.000 claims 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 5
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 2
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims 1
- 230000000798 anti-retroviral effect Effects 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003084 hiv integrase inhibitor Substances 0.000 claims 1
- 239000004030 hiv protease inhibitor Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 claims 1
- 229960004710 maraviroc Drugs 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035515 penetration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- AIDS & HIV (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/913,300 US9090686B2 (en) | 2009-04-29 | 2010-10-27 | Antibodies for the treatment of HIV |
| US12/913,300 | 2010-10-27 | ||
| PCT/EP2011/068905 WO2012055980A1 (en) | 2010-10-27 | 2011-10-27 | Antibodies for the treatment of hiv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013122770A true RU2013122770A (ru) | 2014-12-10 |
Family
ID=44913256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013122770/10A RU2013122770A (ru) | 2010-10-27 | 2011-10-27 | Антитела для лечения вич |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2632953A1 (enExample) |
| JP (1) | JP2014504147A (enExample) |
| KR (1) | KR20140009174A (enExample) |
| CN (1) | CN103180342A (enExample) |
| AU (1) | AU2011322508A1 (enExample) |
| CA (1) | CA2814908A1 (enExample) |
| MX (1) | MX2013004710A (enExample) |
| RU (1) | RU2013122770A (enExample) |
| WO (1) | WO2012055980A1 (enExample) |
| ZA (1) | ZA201302639B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2961427B1 (en) * | 2013-02-28 | 2020-03-25 | Gnvie, Llc | Hiv antigens and antibodies |
| AU2014359085B2 (en) * | 2013-12-08 | 2017-11-02 | Peptcell Limited | HIV antigens and antibodies and compositions, methods and uses thereof |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US20050002939A1 (en) * | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
| MX2010012435A (es) * | 2008-05-14 | 2011-05-03 | Lilly Co Eli | Anticuerpos anti-cxcr4. |
| EP2172485A1 (en) * | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
| JP2012158521A (ja) * | 2009-04-17 | 2012-08-23 | Kureha Corp | 外用剤 |
| EP2246364A1 (en) * | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
| EP2371863A1 (en) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
-
2011
- 2011-10-27 KR KR20137011891A patent/KR20140009174A/ko not_active Withdrawn
- 2011-10-27 MX MX2013004710A patent/MX2013004710A/es unknown
- 2011-10-27 AU AU2011322508A patent/AU2011322508A1/en not_active Abandoned
- 2011-10-27 RU RU2013122770/10A patent/RU2013122770A/ru not_active Application Discontinuation
- 2011-10-27 CN CN2011800520640A patent/CN103180342A/zh active Pending
- 2011-10-27 JP JP2013535444A patent/JP2014504147A/ja active Pending
- 2011-10-27 CA CA 2814908 patent/CA2814908A1/en not_active Abandoned
- 2011-10-27 EP EP11779612.8A patent/EP2632953A1/en not_active Withdrawn
- 2011-10-27 WO PCT/EP2011/068905 patent/WO2012055980A1/en not_active Ceased
-
2013
- 2013-04-12 ZA ZA2013/02639A patent/ZA201302639B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011322508A1 (en) | 2013-05-02 |
| CN103180342A (zh) | 2013-06-26 |
| MX2013004710A (es) | 2013-08-29 |
| KR20140009174A (ko) | 2014-01-22 |
| EP2632953A1 (en) | 2013-09-04 |
| ZA201302639B (en) | 2013-11-27 |
| JP2014504147A (ja) | 2014-02-20 |
| CA2814908A1 (en) | 2012-05-03 |
| WO2012055980A1 (en) | 2012-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017114341A (ru) | Антитела к pd-l1, связывающие pd-l1 собаки | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| JP2021506244A5 (enExample) | ||
| RU2019141289A (ru) | АНТИ-SIRPα АНТИТЕЛА | |
| RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| PE20120835A1 (es) | Anticuerpos anti-tnf-alfa y sus usos | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| NZ596712A (en) | Anti cxcr4 antibodies for the treatment of hiv | |
| MX2018014714A (es) | Composiciones para inhibir la activacion del complemento dependiente de la masp-2. | |
| RU2012142231A (ru) | Антитела против csf-1r человека и их применение | |
| RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| RU2009117237A (ru) | Средство для профилактики/лечения рака | |
| JP2016527225A5 (enExample) | ||
| RU2018106456A (ru) | Антитело к epha4 | |
| UA108466C2 (en) | Antibody antagonises c-Met | |
| PE20210554A1 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
| IL250289B2 (en) | Antibodies against angiopoietin-like 4 and methods of use | |
| PE20221511A1 (es) | Anticuerpos anti-ly6g6d y metodos de uso | |
| CR20240482A (es) | Anticuerpos anti-tl1a y métodos de uso de los mismos | |
| CN111712521A (zh) | Cd38蛋白抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160321 |